| Zhou, Hongsheng |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Relapsed or Refractory Acute Lymphoblastic Leukemia | 09/22 | 12/26 | | |
NCT05667506: A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) |
|
|
| Recruiting | 1/2 | 47 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | B-cell Acute Lymphoblastic Leukemia | 12/24 | 12/26 | | |
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 41 | RoW | GNC-038 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 06/25 | 11/25 | | |
| Weng, Jianyu |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 92 | RoW | TQ05105 Tablets, TQB3617 Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/26 | 04/27 | | |
NCT05320809: Study of 3D189 in Patients With Hematologic Malignancies |
|
|
| Active, not recruiting | 1 | 15 | RoW | 3D189 | 3D Medicines | Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome | 12/24 | 12/24 | | |
| Wei, Xudong |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Relapsed or Refractory Acute Lymphoblastic Leukemia | 09/22 | 12/26 | | |
| Recruiting | 1/2 | 284 | RoW | APG-2575, Reduced-dose HHT, standard-dose HHT, Azacitidine | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy | 08/25 | 08/26 | | |
NCT06052813: A Study of BN104 in the Treatment of Acute Leukemia |
|
|
| Recruiting | 1/2 | 90 | RoW | BN104 | BioNova Pharmaceuticals (Shanghai) LTD. | ALL, Adult, AML, Adult | 06/26 | 06/27 | | |
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
|
|
| Recruiting | 1 | 98 | RoW | HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study | Hutchmed | Hematological Malignancies | 10/27 | 12/27 | | |
NCT05641259: A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML |
|
|
| Recruiting | 1 | 198 | RoW | LP-108, Azacitidine | Guangzhou Lupeng Pharmaceutical Company LTD. | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 12/24 | 12/25 | | |
| Recruiting | 1 | 48 | RoW | TQB2928 Injection + Azacitidine for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 05/25 | 05/25 | | |
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
|
|
| Recruiting | 1 | 102 | RoW | APG-115, Azacitidine, Cytarabine | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | 12/25 | 12/25 | | |
NCT06472479: LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma |
|
|
| Not yet recruiting | N/A | 66 | RoW | LCAR-M61S cells preparation, Cyclophosphamide, Fludarabine, LCAR-M61D cells preparation | The First Affiliated Hospital with Nanjing Medical University, Nanjing Legend Biotech Co. | Relapsed/Refractory Multiple Myeloma | 08/28 | 10/29 | | |
